Elina Salmi

Elina Salmi

Auto-generated profile, based on publicly available information

Elina Salmi

Turku PET Centre, University of Turku and Department of Otorhinolaryngology--Head and Neck Surgery, Turku University Hospital, Finland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in NeuroImage
Verified
Journal Article
Closed access
ESElina Salmi
Elina Salmi
SASargo Aalto
Sargo Aalto
JHJussi Hirvonen
Jussi Hirvonen
JLJaakko W. Långsjö
Jaakko W. Långsjö
AMAnu T. Maksimow
Anu T. Maksimow
HSHarry Scheinin
Harry Scheinin

1 January 2008 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
ESElina Salmi
Elina Salmi
RLRuut M. Laitio
Ruut M. Laitio
SASargo Aalto
Sargo Aalto
AMAnu T. Maksimow
Anu T. Maksimow
JLJaakko W. Långsjö
Jaakko W. Långsjö
HSHarry Scheinin
Harry Scheinin
The noble gas xenon acts as an anesthetic with favorable hemodynamic and neuroprotective properties. Based on animal and in vitro data, it is thought to exert its anesthetic effects by inhibiting glutamatergic signaling, but effects on gamma-aminobutyric acid type A (GABA(A)) receptors also have been reported. The mechanism of anesthetic action of xenon in the living human brain still remains to be determined. We used the specific GABA(A) receptor benzodiazepine-site ligand 11C-flumazenil and positron emission tomography to study the GABAergic effects of xenon in eight healthy male volunteers. Each subject underwent two dynamic 60-min positron emission tomography studies awake and during approximately one minimum alveolar concentration of xenon (65%). Bispectral index was recorded. Cortical and subcortical gray matter regions were analyzed using both automated regions-of-interest analysis and voxel-based analysis. During anesthesia, the mean +/- sd bispectral index was 23 +/- 7, and there were no significant changes in heart rate or mean arterial blood pressure. Xenon did not significantly affect 11C-flumazenil binding in any brain region. Xenon did not affect 11C-flumazenil binding in the living human brain, indicating that the anesthetic effect of xenon is not mediated via the GABA(A) receptor system.

1 September 2005 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
ESElina Salmi
Elina Salmi
JLJaakko W Långsjö
Jaakko W Långsjö
SASargo Aalto
Sargo Aalto
KNKjell Någren
Kjell Någren
LMLiisa Metsähonkala
Liisa Metsähonkala
HSHarry Scheinin
Harry Scheinin
Positron emission tomography (PET) studies suggest that propofol and inhaled anesthetics increase (11)C-flumazenil binding in the living human brain, thus supporting the involvement of gamma-aminobutyric acid type A (GABA(A)) receptors in the mechanism of action of these drugs. Ketamine produces its anesthetic effects primarily by N-methyl-d-aspartate receptor antagonism, but it may also have GABA(A) receptor agonistic properties. By using PET, we studied the cerebral (11)C-flumazenil binding in 10 healthy subjects before and during a subanesthetic racemic ketamine infusion reaching a serum concentration of 350 +/- 42 ng/mL. Ketamine did not affect (11)C-flumazenil binding to GABA(A) receptor in the brain, indicating that this mechanism is of minor importance in the actions of subanesthetic ketamine.